Core Viewpoint - The acquisition of LENSAR, INC. by Alcon Inc. remains incomplete as of mid-December, despite earlier expectations to finalize it by year-end [1]. Group 1 - Alcon Inc. is in the process of acquiring LENSAR, INC. [1] - The acquisition was initially anticipated to be completed by the end of the year [1].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 32-0125724 (State or other jurisdiction ...

LENSAR® Reports Third Quarter 2025 Results and Provides Business Update Third Quarter 2025 Financial Results Total revenue for the quarter ended September 30, 2025 was $14.3 million, an increase of $0.8 million, or 6%, compared to total revenue of $13.5 million for the quarter ended September 30, 2024. The increase in the third quarter of 2025 was primarily due to increased procedure volume. Worldwide procedure volume increased by approximately 11% in the third quarter of 2025 as compared to 2024. During th ...

Core Insights - LENSAR, Inc. reported a total revenue of $14.3 million for Q3 2025, marking a 6% increase from $13.5 million in Q3 2024, primarily driven by an 11% increase in worldwide procedure volume [3][4] - The installed base of ALLY Robotic Cataract Laser Systems grew by 77% year-over-year, with 185 systems installed as of September 30, 2025 [3][4] - The company is in the process of being acquired by Alcon, with expectations for the transaction to close in Q1 2026 [2][3] Financial Performance - Total revenue for Q3 2025 was $14.3 million, up from $13.5 million in Q3 2024, driven by increased procedure volume [3][4] - Recurring revenue accounted for 75% of total revenue in Q3 2025, compared to 73% in Q3 2024 [4] - The net loss for Q3 2025 was $3.7 million, or ($0.31) per share, compared to a net loss of $1.5 million, or ($0.13) per share, in Q3 2024 [6][18] Operational Highlights - The company placed 18 ALLY Systems in Q3 2025, contributing to a total installed base of approximately 425 laser systems, a 20% increase from the previous year [3][4] - Selling, general, and administrative expenses rose to $12.0 million in Q3 2025, up from $6.1 million in Q3 2024, largely due to acquisition-related costs [5][18] - Research and development expenses increased by 14% to $1.4 million in Q3 2025 compared to $1.2 million in Q3 2024 [5][18] Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and investments totaling $16.9 million, down from $22.5 million at the end of 2024 [8][20] - The cash balance decreased by approximately $3.4 million during Q3 2025 [8]

Financial Performance - Total revenue for Q2 2025 was $13,935,000, a 10.3% increase from $12,636,000 in Q2 2024[23] - Product revenue increased to $10,910,000 in Q2 2025, up 14.4% from $9,534,000 in Q2 2024[23] - For the three months ended June 30, 2025, total revenue was $12,290,000, an increase from $10,684,000 in the same period of 2024, representing a growth of 15%[62] - Revenue for the six months ended June 30, 2025, increased by 21% to $28.1 million compared to $23.2 million for the same period in 2024[134] - Total revenue for the three months ended June 30, 2025 increased by $1.3 million, or 10%, compared to the same period in 2024, reaching $13.935 million[153] - Product revenue for the three months ended June 30, 2025 increased by $1.4 million, or 14%, primarily due to increased ALLY System placements and increased procedure volume of $1.5 million[153] Losses and Expenses - Net loss for the six months ended June 30, 2025, was $29,109,000, compared to a net loss of $11,200,000 for the same period in 2024[28] - Operating expenses rose to $13,313,000 in Q2 2025, a 10.1% increase from $12,093,000 in Q2 2024[23] - The net loss attributable to common stockholders for the three months ended June 30, 2025, was $1,764,000, compared to a net loss of $9,043,000 for the same period in 2024, indicating a significant improvement[123] - Net cash used in operating activities for the six months ended June 30, 2025 was $11.9 million, compared to $9.1 million for the same period in 2024[191][192] Assets and Liabilities - Cash and cash equivalents decreased to $7,150,000 as of June 30, 2025, down from $16,263,000 at the end of 2024[25] - Total assets increased to $70,414,000 as of June 30, 2025, compared to $66,297,000 at the end of 2024[25] - Current liabilities surged to $30,090,000 as of June 30, 2025, up from $15,003,000 at the end of 2024[25] - The company had a total stockholders' deficit of $23,052,000 as of June 30, 2025, compared to a total stockholders' equity of $4,862,000 at the end of 2024[25] - As of June 30, 2025, accounts receivable, net, was $4,987,000, down from $6,085,000 as of December 31, 2024[63] Merger and Acquisition - The company has entered into a merger agreement with Alcon Research, LLC, where each share of common stock will be converted into $14.00 in cash plus a contingent value right of $2.75 upon achieving specific performance metrics[35] - The merger is expected to close in the second half of 2025, subject to regulatory approvals[35] - Acquisition-related costs amounted to $4,174,000 and $8,399,000 for the three and six months ended June 30, 2025, respectively, related to the merger agreement with Alcon[51] - The Company and Alcon received a Second Request from the FTC, extending the waiting period until 30 days after substantial compliance is certified[213] - The Merger Agreement includes a termination fee of approximately $8.5 million, which may discourage third-party acquisition proposals[216] Cash Flow and Financing - Management believes that current cash and investments will be sufficient for operating, investing, and financing cash flows for at least twelve months[39] - The company may need to raise additional capital through equity or debt financings in the future, depending on market conditions[42] - The company raised $20.0 million through a Securities Purchase Agreement, resulting in net proceeds of approximately $19.1 million after offering expenses[187][188] Regulatory and Market Conditions - The U.S. government's trade policy changes have negatively impacted the company's gross margins[39] - Pricing increases in component parts for the ALLY System due to inflation may adversely impact customer demand[38] - The company anticipates ongoing inflationary impacts on costs due to global economic uncertainty, which may affect gross margins[141] Research and Development - Research and development expenses were $1,425,000 in Q2 2025, slightly up from $1,348,000 in Q2 2024[23] - Research and development expenses for the three months ended June 30, 2025 increased by $0.1 million, or 6%, compared to the same period in 2024[171] Stock and Compensation - The total stock-based compensation expense recognized for the three months ended June 30, 2025, was approximately $766,000, compared to $683,000 for the same period in 2024, reflecting an increase of 12.2%[121] - The Company expects to recognize total unrecognized compensation expense of $655 related to stock options over a weighted average period of 1.3 years[110] - As of June 30, 2025, the company had approximately $5,375,000 of total unrecognized compensation expense related to restricted stock units and performance stock units, expected to be recognized over a weighted-average period of 2.9 years[117] Operational Highlights - Installed base of Systems reached approximately 410 as of June 30, 2025[134] - The ALLY System received FDA clearance in June 2022 and is available to U.S. and EU cataract surgeons, with additional regulatory clearances pursued in other countries[132] - The company is expanding its commercial organization, with approximately 75 commercial professionals in the U.S. as of June 30, 2025[133] - The company plans to expand its sales and customer support teams, which will increase revenue and expenses as part of its growth strategy[186]

Exhibit 99.1 LENSAR Reports Second Quarter 2025 Results and Provides Business Update 18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla. (August 7, 2025) – LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company), a global medical technology company focused ...

Core Insights - LENSAR, Inc. reported strong operational performance in Q2 2025, with 18 ALLY Robotic Cataract Laser Systems installed and an additional 18 in backlog, reflecting a 107% growth in the installed base compared to Q2 2024 [1][2] - The company experienced a 23% increase in worldwide procedure volumes compared to the same quarter in the previous year [1][2] - The proposed merger with Alcon has received overwhelming support from shareholders, with over 99% of votes cast in favor, and is expected to close by the end of 2025 [2] Financial Performance - Total revenue for Q2 2025 was $13.9 million, a 10% increase from $12.6 million in Q2 2024, primarily driven by increased procedure volume [3][4] - Recurring revenue accounted for 82% of total revenue in Q2 2025, up from 79% in Q2 2024, with procedure revenue increasing to $8.3 million from $6.9 million year-over-year [4][5] - The net loss for Q2 2025 was $1.8 million, or ($0.15) per share, significantly reduced from a net loss of $9.0 million, or ($0.79) per share, in Q2 2024 [7][20] Operational Highlights - The installed base of ALLY Systems reached approximately 165 units, with a total combined installed base of LENSAR Laser Systems and ALLY Systems increasing to about 410, reflecting a 23% increase year-over-year [3][4] - Selling, general, and administrative expenses rose to $11.7 million in Q2 2025, a 72% increase from $6.8 million in Q2 2024, largely due to acquisition-related costs associated with the merger with Alcon [5][6] - Research and development expenses increased slightly to $1.4 million in Q2 2025 from $1.3 million in Q2 2024 [6] Market Position - LENSAR's laser systems accounted for over 21% of total U.S. cataract procedures in Q2 2025, marking a 3% increase from the previous year [3] - The company continues to focus on advanced robotic laser solutions for cataract treatment, positioning itself as a leader in the medical technology sector [11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...

ORLANDO, Fla. (May 8, 2025) – LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "We had a solid start to 2025, as we successfully placed 40% more ALLY Systems in the first quarter of 2025, compared to the first quarter of 2024. Similarly, we achieved a substantial 34% ...

Core Insights - LENSAR, Inc. reported a strong start to 2025 with a 34% increase in revenue and a 33% rise in worldwide procedure volumes compared to the first quarter of 2024 [2][3] - The company placed 14 ALLY Robotic Laser Cataract Systems in the first quarter of 2025, contributing to a total installed base of approximately 150 systems [3][4] - The company is in the process of a proposed merger with Alcon Research, LLC, which has led to increased acquisition-related costs [4][8] Financial Performance - Total revenue for Q1 2025 was $14.2 million, up from $10.6 million in Q1 2024, marking a $3.6 million increase [3][4] - Recurring revenue for the quarter was $11.5 million, representing an 81% recurring revenue percentage, although this is down from 90% in the previous year [4] - The net loss for Q1 2025 was $27.3 million, compared to a net loss of $2.2 million in Q1 2024, primarily due to changes in warrant liability [6][7] Operational Highlights - The company’s laser systems accounted for approximately 22% of total U.S. procedures in Q1 2025 [3] - Selling, general, and administrative expenses increased by 64% to $11.1 million, largely due to acquisition-related costs associated with the Alcon merger [4] - Research and development expenses rose slightly to $1.5 million, a 6% increase from the previous year [5] Cash Position - As of March 31, 2025, LENSAR had cash, cash equivalents, and investments totaling $25.2 million, an increase from $22.5 million at the end of 2024 [8]